抗病毒对乙肝后中晚期肝癌患者化疗的作用  

Anti-HBV Virus on Efficacy of Chemotherapy for Advanced HCC

作　　者：陈武松[1] 邱其武[1] 韩琴丽[1] 钟卫卫[1] 

机构地区：[1]湖北省荆门市第一人民医院,448000

出　　处：《实用癌症杂志》2016年第3期490-492,共3页The Practical Journal of Cancer

摘　　要：目的研究抗乙肝病毒治疗对乙肝中晚期肝癌患者化疗的疗效影响,探讨化疗联合应用抗乙肝病毒治疗的必要性及有效性。方法收集行化疗治疗同时抗乙肝病毒治疗、病例资料完整的乙肝后中晚期肝癌患者,以同期仅行化疗治疗的乙肝后中晚期肝癌患者的临床资料作为对照。比较2组患者的肿瘤治疗效果、生存期等指标。结果抗病毒治疗组3个月、6个月病情稳定(SD)率分别为66.39%、45.08%,明显高于非抗病毒治疗组(P<0.05)。6个月抗病毒治疗组AFP水平明显低于非抗病毒治疗组,差异具有统计学意义。3个月、6个月后抗病毒治疗组HBV-DNA转阴率分别是为30.33%,49.18%,均低于非抗病毒治疗组。抗病毒治疗组的累积生存率均高于非抗病毒治疗组的患者。结论对于中晚期乙肝后肝癌患者,应用抗病毒药物是必要的,它可以提高综合治疗效果、有效改善预后。Objective To study the efficacy of chemotherapy combined with anti-HBV for terminal-stage HCC with HBV, and its necessity and effectiveness. Methods Middle-late HCC patients with HBV treated with chemotherapy and antiviral therapy were the study group, and patients received only chemotherapy in the same period were the control group. Efficacy and survival time of the 2 groups were compared. Results The stable condition（SD） rate after 3 months,6 months of the treatment group were 66.39% ,45.08% ,which were significantly higher than those of the control group（ P 〈 0.05 ）. The AFP level after 6 months in the treatment group was obviously lower than that of the control group, the difference was statistically significant. The HBV-DNA overcast rate 3 months and 6 months after antiviral treatment were 30.33% ,49.18% ,which were lower than those of the control group. The cumulative survival rate of the treatment group was higher than that of the control group. Conclusion Antiviral drug for middle-late stage HCC patients with HBV can improve the effect of comprehensive treatment and prognosis.

关 键 词：抗HBV病毒 化疗 乙肝中晚期肝癌 效果 

分 类 号：R735.7[医药卫生—肿瘤]